Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 83,934 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Terminated Not applicable Interventional Results available

Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity

NCT03261531
View directory record Official record
Conditions
Obesity
Interventions
Transcutaneous electrical nerve stimulation (TENS)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 30, 2026, 8:10 PM EDT
Recruiting No phase listed Observational

Validation of the Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS) Tool for Use in a Physical Medicine Rehabilitation Clinic

NCT06329531
View directory record Official record
Conditions
Cancer, Occupational Therapy
Interventions
Screen of Cancer Survivorship - Occupational Therapy Services (SOCS-OTS)
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Recruiting Phase 2 Interventional

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

NCT03266653
View directory record Official record
Conditions
Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Interventions
cytotoxic t-lymphocytes
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 2 Interventional

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

NCT00480753
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 30, 2026, 8:10 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

NCT04868253
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Disorder
Interventions
EMB-01
Drug
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 30, 2026, 8:10 PM EDT
Not listed Not applicable Interventional Results available

The MOTION Study - Treatment of LSS With the MILD Procedure

NCT03610737
View directory record Official record
Conditions
Spinal Stenosis, Lumbar Region, With Neurogenic Claudication
Interventions
MILD Procedure, Conventional Medical Management (CMM)
Device · Other
Lead sponsor
Vertos Medical, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
18
States / cities
Newport Beach, California • Colorado Springs, Colorado • Lakeland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 30, 2026, 8:10 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Curio Digital Therapy for the Treatment of Post-partum Depression

NCT05958095
View directory record Official record
Conditions
PostPartum Depression
Interventions
MamaLift Plus, Digital Sham App
Device
Lead sponsor
Healthcare Innovation Technology Lab
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 30, 2026, 8:10 PM EDT
Completed No phase listed Observational

Long Term Effects of Treating Submassive Pulmonary Embolism With Ultra-sound Accelerated Thrombolysis

NCT01899339
View directory record Official record
Conditions
Submassive Pulmonary Embolism
Interventions
submassive PA treatment with Ekosonic endo device
Other
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01756339
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin, Placebo to match solithromycin
Drug · Other
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Glendale, California • Los Angeles, California • Mission Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 30, 2026, 8:10 PM EDT
Not listed Phase 4 Interventional

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

NCT00826527
View directory record Official record
Conditions
Urinary Frequency, Urinary Urgency, Nocturia
Interventions
Solifenacin PO
Drug
Lead sponsor
Seattle Urology Research Center
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Oct 30, 2026, 8:10 PM EDT
Active, not recruiting Phase 4 Interventional

Connective Tissue Matrix for Rotator Cuff Tendinopathy

NCT06160427
View directory record Official record
Conditions
Tendinopathy, Shoulder Pain, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis
Interventions
CTM Boost, PRP
Biological
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 30, 2026, 8:10 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)

NCT03241927
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab
Biological
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

NCT02463227
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Not applicable Interventional

Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial)

NCT05716542
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
Physical Activity Intervention
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Not applicable Interventional

A Remote, Decentralized Opioid Use Disorder Study to Evaluate Patient Engagement With a Game-Based Digital Therapeutic

NCT04542642
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
reSET-O, PEAR-008
Device
Lead sponsor
Pear Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
New York, New York • Gig Harbor, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 30, 2026, 8:10 PM EDT
Recruiting Phase 2Phase 3 Interventional

Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.

NCT07276542
View directory record Official record
Conditions
Phantom Limb Syndrome With Pain
Interventions
IM ketamine in dose finding and then continuation
Drug
Lead sponsor
The Ketamine Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Sacramento, California • San Anselmo, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

NCT01397786
View directory record Official record
Conditions
Schizophrenia
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Not applicable Interventional Results available

Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation

NCT04190186
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
Insertable Cardiac Monitor
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Ypsilanti, Michigan • Tupelo, Mississippi • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 30, 2026, 8:10 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

NCT04644770
View directory record Official record
Conditions
Prostatic Neoplasms, Adenocarcinoma
Interventions
JNJ-69086420, JNJ-78278343, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00121173
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 30, 2026, 8:10 PM EDT
Recruiting No phase listed Observational

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

NCT05916469
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions
Levonorgestrel Intrauterine System, Norethindrone Acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
10 Years to 24 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 2 Interventional

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

NCT00068783
View directory record Official record
Conditions
Recurrent Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin, Stage III Neuroendocrine Carcinoma of the Skin
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 30, 2026, 8:10 PM EDT
Terminated Phase 2 Interventional Results available

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

NCT00450983
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Genetic + 3 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 30, 2026, 8:10 PM EDT